Related Experiment Video
Updated: Jan 5, 2026

Visualization of DNA Repair Proteins Interaction by Immunofluorescence
Published on: June 26, 2020
Targeting RAD51 enhances chemosensitivity of adult T‑cell leukemia‑lymphoma cells by reducing DNA double‑strand break
Meng Yang1, Xiaoxue Tian1, Zhuoyi Fan1
1Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R China.
Abstract:
RAD51, is a key homologous recombination protein that repairs DNA damage and maintains gene diversity and stability. Previous studies have demonstrated that the over‑expression of RAD51 is associated with chemotherapy resistance of tumor cells to chemotherapy, and enhanced activity of DNA damage repair (DDR) systems contributes to resistance of adult T‑cell leukemia‑lymphoma (ATL) resistance to chemotherapy. Thus, targeting RAD51 is a potential strategy for the sensitization of ATL cells to chemotherapeutic drugs by inducing DNA damage. In general, cells can repair minor DNA damage through DDR; however, serious DNA damage may cause cell toxicity in cells which cannot be restored. In the present, down regulation of RAD51 by shRNA and imatinib sensitized Jurkat cells to etoposide by decreasing the activity of homologous recombination (HR). We found that the suppression of RAD51 by shRNA inhibited tumor cells proliferation and enhanced apoptosis of Jurkat cells after etoposide treatment. Importantly, downregulation of RAD51 by imatinib obviously increased the apoptosis of Jurkat cell after etoposide treatment. These results demonstrated that RAD51 may be of great value to as a novel target for the clinical treatment of adult T‑cell leukemia‑lymphoma (ATL), and it may improve the survival of leukemia patients.
Insights
Targeting RAD51, a key DNA repair protein, can sensitize adult T-cell leukemia-lymphoma cells to chemotherapy. Suppressing RAD51 enhances cancer cell death and may improve patient survival.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- RAD51 is a crucial homologous recombination protein involved in DNA repair, gene stability, and diversity.
- Overexpression of RAD51 is linked to chemotherapy resistance in tumor cells.
- Enhanced DNA damage repair (DDR) activity contributes to chemotherapy resistance in adult T-cell leukemia-lymphoma (ATL).
Purpose of the Study:
- To investigate the potential of targeting RAD51 to sensitize ATL cells to chemotherapy.
- To explore the role of RAD51 in DNA damage repair and its impact on ATL cell survival.
- To evaluate the efficacy of RAD51 downregulation in combination with etoposide treatment.
Main Methods:
- Utilized short hairpin RNA (shRNA) to downregulate RAD51 expression.
- Administered imatinib to inhibit RAD51 activity.
- Treated Jurkat cells (a model for ATL) with etoposide.
- Assessed homologous recombination (HR) activity, cell proliferation, and apoptosis.
Main Results:
- Downregulation of RAD51 by shRNA and imatinib sensitized Jurkat cells to etoposide by reducing HR activity.
- Suppression of RAD51 inhibited tumor cell proliferation and increased apoptosis after etoposide treatment.
- Imatinib-mediated RAD51 downregulation significantly enhanced etoposide-induced apoptosis in Jurkat cells.
Conclusions:
- RAD51 is a promising therapeutic target for adult T-cell leukemia-lymphoma (ATL).
- Targeting RAD51 can enhance the efficacy of chemotherapy by inducing DNA damage and promoting cancer cell death.
- Inhibition of RAD51 may improve clinical outcomes and survival rates for leukemia patients.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Fixing Double-strand Breaks

